21 Feb 2024

Bavarian Nordic’s revenue soars post-mpox outbreaks

Bavarian Nordic reported record financial results in 2023, earning a preliminary revenue of DKr7.06bn ($1bn) compared to DKr3.15bn ($456m) in 2022, primarily driven by a surge in sales of smallpox…

21 Feb 2024

Polpharma looks to challenge Takeda’s Entyvio in IBD

Netherland-based Polpharma Biologics has released topline results from the Phase III trial of its biosimilar candidate PB016, showing that the biosimilar is non-inferior to its reference biologic, Takeda Pharmaceuticals’ Entyvio…

21 Feb 2024

Genezen to license CSL’s lentiviral vector production system

Contract development and manufacturing organisation (CDMO) Genezen has announced plans to license CSL’s Cytegrity stable lentivirus production system. The advanced inducible technology produces lentiviral vectors (LVVs), which are vital for…

[ajax_load_more post_type="post" taxonomy="category" taxonomy_terms="company-news, contract-news, deal-news, industry-news, news" taxonomy_operator="IN" images_loaded="true" posts_per_page="20" offset="7" pause="true" scroll="false" button_label="Load More Stories"]